Product Highlight - SOLIQUA

17 Aug 2022
Product Highlight - SOLIQUA

                                                                                             Experience the Power to Control!1,2,3
                                                                                                Now available at a lower price!4

  •  Insulin Glargine + Lixisenatide (Soliqua®) 100 u/mL + 50 mcg/ml – NEW SRP Php 1,515 (Savings of Php 318 from previous SRP)4
  •  Insulin Glargine + Lixisenatide (Soliqua®) 100 u/mL + 33 mcg/ml – NEW SRP Php 1,313 (Savings of Php 348 from previous SRP)4
  •  Indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemiccontrol when oral antidiabetic drugs or basal insulin alone do not provide adequate
    glycemic control.1-3
  •  Power to control HbA1c with no added risk of hypoglycemia and no weight gain.1-3 

 

REFERENCES:
(1) Soliqua 2018 Prescribing Information.
(2) Rosenstock J et. al. LixiLan-O randomized trial. Diabetes Care. 2016 Nov 1;39(11):2026-35.
(3) Aroda et. al. LixiLan-L randomized trial. Diabetes care. 2016 Nov 1;39(11):1972-80.
(4) Based on Mercury Suggested Retail Price as of July 1, 2020.

This material is strictly for HCPs only.
                                                                                                                                                        MAT-PH-2000218 / VER 1.0 / DA 07-2020 / DM 07-2020


sanofi-aventis PHILS. INC.
21st to 23rd Flr.
One World Place Corporate Offices.
32nd St., Bonifacio Global City
Taguig City 1634, Metro Manila.
Website: www.sanofi.ph

Related MIMS Drugs